logo
China woman suffers brain haemorrhage, in coma after sunbathing to improve health

China woman suffers brain haemorrhage, in coma after sunbathing to improve health

The case of a 67-year-old woman in China who suffered a brain haemorrhage and fell into a coma after sunbathing her back for two hours in scorching heat in a bid to 'cure illnesses' has shocked the nation.
The incident recently unfolded in Zhejiang province, southeastern China, when the woman, surnamed Wang, tried a traditional Chinese medicine (TCM) remedy she had heard about.
The remedy apparently said that 'sunbathing your back can warm the yang energy, dispel dampness and cure illnesses'.
Around noon, Wang lay face-down in an open area outside her home for two hours.
Experts say that when it comes to sunbathing, keeping strict control over the amount of exposure to the sun is vital. Photo: Shutterstock
However, shortly after returning indoors, she collapsed and lost consciousness.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug

South China Morning Post

time7 hours ago

  • South China Morning Post

Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug

First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday. Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday. 3SBio's shares fell 6.41 per cent to HK$28.45 on Friday. The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.

Hong Kong students should avoid ordering takeaway food on mainland China trips, authorities say
Hong Kong students should avoid ordering takeaway food on mainland China trips, authorities say

South China Morning Post

timea day ago

  • South China Morning Post

Hong Kong students should avoid ordering takeaway food on mainland China trips, authorities say

A new guide has advised students from Hong Kong to refrain from ordering food and drinks through delivery platforms during trips to mainland China in the new academic year, in light of reports that more than 100 students taking part in such tours developed gastroenteritis symptoms. Students were also advised not to go to the gym or use recreational facilities in hotels to ensure they have sufficient rest the following day, according to education authorities. The Education Bureau recently uploaded a document for schools in a 'frequently asked questions' format for such trips in the new academic year.

'HK-made Chinese medicines to grow in popularity'
'HK-made Chinese medicines to grow in popularity'

RTHK

timea day ago

  • RTHK

'HK-made Chinese medicines to grow in popularity'

'HK-made Chinese medicines to grow in popularity' Wing Chu (left) says streamlined approval procedures offer more opportunities for Hong Kong-made proprietary Chinese medicines to be sold on the mainland. Photo: RTHK Hong Kong-made proprietary Chinese medicine products have great potential to enter mainland and overseas markets, the Hong Kong Trade Development Council said on Thursday. The mainland, which is the largest proprietary Chinese medicine market valued at 450 billion yuan, has streamlined the registration and approval procedures for products from Hong Kong. At a press conference, the council's principal economist of Greater China, Wing Chu, said Hong Kong's exports of proprietary Chinese medicines totalled HK$2.88 billion last year. More than 70 percent of the city's products were exported to the mainland, followed by 20 percent to Macau. Although the mainland mainly relies on its own drug production and only imports a small amount of Chinese medicines, over half of its imported proprietary Chinese medicines are from Hong Kong, Chu said. He added that the streamlined approval procedures offer more opportunities for Hong Kong businesses to expand into the Greater Bay Area and other mainland cities. 'Maybe Hong Kong-produced products are not the cheapest in the market, and there are a lot of alternative choices over there, but Hong Kong proprietary Chinese medicine products have a [good reputation] in mainland China, especially in the southern part of mainland China,' he said. Chu said there is also demand for Chinese medicines in overseas markets, particularly in Southeast Asia. 'But apart from this, there is also a lot of demand … even in the US or some European countries. They also have a demand for the traditional Chinese medicines. And this actually provides a very good market potential for us to explore,' he said. The council also said the opening of Hong Kong's first Chinese medicine hospital at the end of the year will help make proprietary Chinese medicines even more popular.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store